COO

The Cooper Companies, Inc.

$63.57

-0.56%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc.

Source: Yahoo Finance
AI summary

Price & performance

1M+9.0%
3M-17.0%
YTD-27.3%
1Y-21.4%
52-week range—
Beta0.72
Full chart and returns against a benchmark

Q-Score

56/ 100

Quality against peers; 50 is the peer median.

Growth51
Risk70
Performance32
Valuation71
Profitability63
Leverage52
Sentiment11
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$4.1B+5.1%
Net income$374.9M-4.4%
Net margin9.2%-0.9 pts
Historical fundamentals

Revenue exposure

50%of revenue from outside the US
United States50%
Europe31%
Rest of the World19%
Regions, segments, customers and suppliers

Valuation

COOIndustryP/E21.2049.36P/S2.853.73EV/EBITDA15.6023.12P/B1.453.92PEG0.530.53
Dividend yield0.00%
Every valuation metric

Earnings

Dec 3next report, after the close
EPS estimate$1.07
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate